Histopathology-based breast cancer prediction using deep learning methods for healthcare applications
Frontiers in Oncology · 04.06.2024 · 14
DOI: 10.3389/fonc.2024.1300997 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 04.06.2024. Verfasst von Prabhu Ramamoorthy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Electronics and Communication Engineering, Gnanamani College of Technology, Namakkal, India. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Saud University.
Abstract (Originalsprache)
Breast cancer (BC) is the leading cause of female cancer mortality and is a type of cancer that is a major threat to women's health. Deep learning methods have been used extensively in many medical domains recently, especially in detection and classification applications. Studying histological images for the automatic diagnosis of BC is important for patients and their prognosis. Owing to the complication and variety of histology images, manual examination can be difficult and susceptible to errors and thus needs the services of experienced pathologists. Therefore, publicly accessible datasets called BreakHis and invasive ductal carcinoma (IDC) are used in this study to analyze histopathological images of BC. Next, using super-resolution generative adversarial networks (SRGANs), which create high-resolution images from low-quality images, the gathered images from BreakHis and IDC are pre-processed to provide useful results in the prediction stage. The components of conventional generative adversarial network (GAN) loss functions and effective sub-pixel nets were combined to create the concept of SRGAN. Next, the high-quality images are sent to the data augmentation stage, where new data points are created by making small adjustments to the dataset using rotation, random cropping, mirroring, and color-shifting. Next, patch-based feature extraction using Inception V3 and Resnet-50 (PFE-INC-RES) is employed to extract the features from the augmentation. After the features have been extracted, the next step involves processing them and applying transductive long short-term memory (TLSTM) to improve classification accuracy by decreasing the number of false positives. The results of suggested PFE-INC-RES is evaluated using existing methods on the BreakHis dataset, with respect to accuracy (99.84%), specificity (99.71%), sensitivity (99.78%), and F1-score (99.80%), while the suggested PFE-INC-RES performed better in the IDC dataset based on F1-score (99.08%), accuracy (99.79%), specificity (98.97%), and sensitivity (99.17%).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Electronics and Communication Engineering, Gnanamani College of Technology, Namakkal, India.
- Department of Computer Science and Engineering, Sri Venkateswara College of Engineering, Tirupathi, India.
- Department of Statistics and Operations Research, College of Science, King Saud University, Riyadh, Saudi Arabia.
- Department of Mathematics, Faculty of Science, Mansoura University, Mansoura, Egypt.
Förderung
- King Saud University
Zitieren
APA
Ramamoorthy, P., Ramakantha Reddy, B. R., Askar, S. S., & Abouhawwash, M. (2024). Histopathology-based breast cancer prediction using deep learning methods for healthcare applications. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1300997
Vancouver
Ramamoorthy P, Ramakantha Reddy BR, Askar SS, Abouhawwash M. Histopathology-based breast cancer prediction using deep learning methods for healthcare applications. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1300997
BibTeX
@article{Ramamoorthy2024,
author = {Ramamoorthy, Prabhu and Ramakantha Reddy, Buchi Reddy and Askar, S S and Abouhawwash, Mohamed},
title = {Histopathology-based breast cancer prediction using deep learning methods for healthcare applications},
journal = {Frontiers in Oncology},
year = {2024},
volume = {14},
doi = {10.3389/fonc.2024.1300997}
}
EUVIMED